ALAUNOS THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | -1.57% |
|
-3.85% | +17.87% |
| Apr. 01 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to Ziopharm Oncology, I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.27
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.87% | 20.34M | |
| +4.42% | 111B | |
| +10.95% | 105B | |
| -12.01% | 22.34B | |
| -3.81% | 21.93B | |
| -5.89% | 18.59B | |
| -36.52% | 18.12B | |
| -10.04% | 16.96B | |
| +3.07% | 13.7B | |
| +37.10% | 12.45B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Transcript : ZIOPHARM Oncology, Inc., Q4 2020 Earnings Call, Feb 25, 2021